<DOC>
	<DOCNO>NCT02430350</DOCNO>
	<brief_summary>The primary objective study confirm efficacy compound Edaravone Injection via intravenous infusion every 12 hour patient Acute Ischemic Stroke ( AIS ) double-blind , active-controlled manner . The study also examine safety compound Edaravone Injection AIS patient .</brief_summary>
	<brief_title>Study Compound Edaravone Injection Treatment Acute Ischemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Phenylmethylpyrazolone</mesh_term>
	<mesh_term>Antipyrine</mesh_term>
	<criteria>Hospitalized patient , diagnose ischemic stroke ; Onset stroke less equal 48 hour ; There clear sign neurological deficit : 4≤NIHSS score≤24 , also , sum NIHSS score upper limb lower limb great equal 2 ; Patients sign write inform consent Cranial CT scan find intracranial bleed disorder : hemorrhagic stroke , epidural hematoma , intracranial hematoma , intraventricular hemorrhage , subarachnoid hemorrhage ; Iatrogenic stroke ; Severe disturbance consciousness : NIHSS category 1a consciousness great 1； The mRS score prior onset great 1 ; Transient ischemic attack ( TIA ) ; SBP blood pressure control still great equal 220 mmHg , DBP blood pressure control still great equal 120 mmHg ; Patients severe mental disorder dementia ; ALT AST great 2.0×ULN previously know liver disease , acute hepatitis , chronic active hepatitis , liver cirrhosis ; Serum Creatinine ( SCr ) great 1.5×ULN , Creatinine Clearance ( CrCl ) less 50 ml/min previously know severe renal disease ; Therapeutic neuroprotective agent apply onset stroke , include commercially available edaravone , nimodipine , ganglioside , citicoline , piracetam , butyl benzene peptide , Urinary Kallidinogenase ; Arterial venous thrombolytic therapy apply onset stroke ; Patients malignant tumor receive concurrent antitumor treatment ; Patients severe systemic disease , life expectancy le 90 day ; allergic edaravone , ( + ) Borneol related excipients ; Pregnant lactate woman ; Have major surgery within 4 week enrollment ; Participated clinical study within 30 day randomization ; participate clinical trial present ; The investigator consider patient suitable trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>